What Is the Wolverine Stack?

1. What is in the Wolverine stack, GLOW and KLOW?

The names are marketing, not pharmacology, but the contents are consistent across sellers:

A consumer guide from Superpower defines GLOW as an injectable blend of GHK-Cu, BPC-157 and TB-500 “sold on the research-chemical market,” and KLOW as the same three plus KPV. FDA’s own BPC-157 briefing documents websites selling BPC-157 and TB-500 as combined “multiple-API” injections, nasal sprays and capsules, some labeled “for research purposes only and not for human or veterinary use.” It also quotes a clinic describing BPC-157 as the “wolverine compound.” The KPV briefing found KPV promoted alongside BPC-157, TB-500 and other substances as a “regenerative combo.”

One naming trap matters. TB-500 is not thymosin beta-4. Thymosin beta-4 is a 43-amino-acid protein; TB-500 is a short synthetic fragment of it. Human studies of the full protein, discussed below, cannot be transferred to the fragment. FDA’s TB-500 review calls TB-500 a common name rather than an official drug name and says it is not well characterized chemically.

2. Why would anyone combine them?

The logic offered by sellers is that the peptides act on different parts of healing: BPC-157 on blood-vessel growth and tendon cells, TB-500 on cell migration, GHK-Cu on collagen, KPV on inflammation. If each helps a little, the argument goes, together they help more.

That is a hypothesis, and combination effects are exactly what has to be tested rather than assumed. Two drugs can add up, do nothing extra, or interfere. The only experiment found that directly compared the Wolverine pair with each peptide alone came out against the “more is better” idea (section 4).

Stacking also creates a practical problem. If someone starts two to four peptides at once and something changes, good or bad, there is no way to tell which one caused it. FDA’s briefing describes exactly that situation in an adverse event report (section 7).

3. What does the evidence for each peptide actually show?

BPC-157: many rat studies, a handful of uncontrolled human reports

A 2025 systematic review in orthopedic sports medicine screened 544 articles and included 36 studies: 35 preclinical and 1 clinical. In animals, BPC-157 improved functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injuries. The authors found no clinical safety data and warned that adverse effects are possible from unregulated manufacturing, contamination or unknown clinical safety. Lab work suggests mechanisms, such as increased VEGFR2 signaling and blood-vessel growth, but blood-vessel growth is also why researchers ask about tumor effects, a question no human study has answered.

The pharmacokinetics are also animal-only: in rats and dogs, intact BPC-157 had a half-life under 30 minutes and was quickly broken into small fragments. Human data are limited to small uncontrolled reports, including the knee chart review below and a two-person IV safety pilot; the BPC-157 page covers them in detail. Registered placebo-controlled trials now exist, such as a hamstring strain study listed as recruiting, but none has posted results.

TB-500: no human studies of the fragment

FDA’s July 2026 TB-500 review is blunt: the nominator’s three references were not human studies, and FDA’s own search “did not identify data, such as clinical studies, on the use of TB-500 in humans.” It concluded there is a lack of evidence to evaluate effectiveness.

The animal and lab picture is thin and mixed. A 2024 study found TB-500 is rapidly broken down in rats and that, in cultured fibroblasts, the parent peptide did not show significant wound-closing activity, while one metabolite did. The authors suggested earlier wound-healing reports may reflect that metabolite rather than TB-500 itself.

Full-length thymosin beta-4 has been tested in people, in different forms and for different uses: a 14-day IV safety study in healthy volunteers, a topical gel trial in 73 people with venous leg ulcers, and eye drops for dry eye, a 72-person trial that missed both primary endpoints. Those trials tell us about a different molecule given by different routes; they do not validate injected TB-500. The first registered trial of the fragment itself, a phase 1/2 placebo-controlled study in adults with stable cardiovascular disease, was recruiting in November 2026.

GHK-Cu: small topical skin studies

A 2026 systematic review of GHK-Cu in aesthetic medicine found 20 studies, 18 preclinical and only 2 randomized trials, all on skin. In one of those trials, after CO2 laser resurfacing, 13 patients who completed the study showed no objective difference in redness, wrinkles or skin quality with GHK-Cu products, although patient satisfaction was higher. That is a cream on the face, not an injection for tendons. FDA’s safety summary lists immune-reaction concerns from aggregation and impurities for injectable GHK-Cu and notes limited human safety data.

KPV: mouse colitis and lab work

KPV’s best-known study showed that, in cell culture and two mouse colitis models, KPV given in drinking water reduced intestinal inflammation through the PepT1 transporter. FDA’s KPV review found no information on use in humans, and its safety summary states that FDA has not identified any human exposure data for KPV by any route.

The overall picture

A 2026 scoping review in the American Journal of Sports Medicine that covered BPC-157, TB-500 and GHK-Cu, among others, summed it up: 67% of publications were animal studies, human studies were “a handful” mostly lacking robust controls, and the claimed recovery benefits “remain unsubstantiated by current human trials.” The authors recommended against using peptide supplements as a replacement for, or add-on to, standard orthopedic care.

4. Has the combination ever been tested?

Only twice in any form, and neither supports the stack.

No human trial of the Wolverine pair, GLOW or KLOW was found on ClinicalTrials.gov or PubMed. The Superpower guide reaches the same conclusion for GLOW and KLOW: no study in humans or animals has tested GHK-Cu, BPC-157 and TB-500 together, or KPV alongside them. Mixing peptides in one vial also raises a chemistry question: whether the ingredients stay stable and at their labeled amounts together. No published stability data for these mixtures were found.

5. What did FDA do in 2023, and what has changed since?

The regulatory story has moved fast, and the headlines have often run ahead of the documents. Here is what the primary records show.

Three points get lost in the coverage. First, leaving category 2 in April 2026 was a procedural consequence of withdrawn nominations, not a finding that the peptides were safe; FDA’s safety summaries stayed on its page, and Polsinelli noted that removal did not authorize compounding. Second, FDA’s own reviewers opposed all three peptides. The BPC-157 briefing cites poor chemical characterization, missing safety and immunogenicity data and insufficient evidence for ulcerative colitis; the TB-500 and KPV briefings cite similar gaps and the absence of human data. Third, advisory votes do not change the law. FDA had not posted minutes or published any proposed rule adding these peptides to the bulks list when this page was checked.

6. What does the October 2026 HHS policy allow, and why does it exclude the stack?

The Federal Register notice, signed by Secretary Kennedy, says HHS “does not intend to take enforcement action” against state-licensed 503A pharmacies, federal facilities or licensed physicians compounding with the peptides in its Appendix A while FDA rulemaking proceeds. It also says compounded drugs are not FDA-approved and that HHS may revisit the policy if a safety signal or quality problem arises. The policy is a draft and is not binding.

According to summaries by Holland & Knight and Arnold & Porter, Appendix A covers six peptides, with routes set in Appendix B:

The policy applies only if all 10 conditions are met, including a patient-specific prescription, bulk ingredient from an FDA-registered, CGMP-compliant manufacturer with a lot-specific certificate of analysis covering identity, purity, potency and contaminants, reporting serious adverse events to MedWatch, and a “Not for resale” label. Two conditions matter directly here:

• One active ingredient per product. Both law-firm summaries state that each compounded product may contain only one Appendix A peptide, so combination products are not covered. A premixed Wolverine, GLOW or KLOW vial is outside the policy.
• GHK-Cu is not on the list. It remains under separate FDA evaluation for non-injectable routes only.

The policy says nothing about the “research use only” products sold directly to consumers online; it addresses pharmacy compounding. Arnold & Porter also notes that the peptides were found poorly characterized, with missing endotoxin, impurity and microbial data, in FDA’s own review. A policy of not enforcing the rules is not evidence that the products work or are safe.

7. What are the quality and contamination risks?

Most Wolverine, GLOW and KLOW products are sold as lyophilized (freeze-dried) powder labeled “for research use only.” That label means the seller is not claiming the product is fit for people, and nothing in that supply chain requires identity, potency, sterility or endotoxin testing. FDA’s safety summaries for BPC-157, TB-500 and GHK-Cu all cite the risk of immune reactions from peptide aggregation (clumping) and peptide-related impurities.

No published lab analysis of commercial Wolverine or GLOW blends was found. Studies of other gray-market peptides show what can go wrong:

• Falsified peptide drugs. A Belgian analysis of the ten most common falsified peptide drugs bought from suspected illegal online pharmacies found large variation in the amount per unit, purity between 5% and 75% for the cysteine-containing peptides, lead in one sample, and arsenic in multiple samples at up to ten times the safety limit for injectable drugs.
• Online semaglutide. In test purchases of semaglutide vials from illegal online pharmacies, content exceeded the label by 28.6% to 38.7%, and bacterial endotoxin, a fever-causing toxin from bacteria, was found in every sample, even though no live microbes grew.

FDA’s BPC-157 briefing also includes a case that shows the attribution problem with blends. A 40-year-old woman injecting a BPC-157 and TB-500 product labeled “for research purposes only” for joint and wound healing developed diffuse skin darkening and darkened gums within a week; the same reaction recurred when she restarted, and stopped when she quit. FDA judged the reaction likely due to the product but noted that, “because the product contained two peptides,” it could not assess which ingredient was responsible. Adverse event data are thin for another reason too: the same briefing notes that 503A compounders generally do not report adverse events to FDA.

8. Is the Wolverine stack banned in sport?

Yes, both core ingredients. The WADA 2026 Prohibited List, in force since January 1, 2026, names:

• BPC-157 under S0, non-approved substances: any substance with no current approval by a government health authority for human therapeutic use.
• Thymosin beta-4 and its derivatives, e.g. TB-500 under S2.3, growth factors and growth factor modulators.

Both S0 and S2 are prohibited at all times, in and out of competition. GHK-Cu and KPV are not named on the list. S0 is written as a catch-all for substances without approval for human therapeutic use, so athletes should not read their absence as permission. WADA published its 2027 list in October 2026, effective January 1, 2027, adding examples and clarifications to S0; the specific new entries could not be checked for this page. Athletes in tested sport should treat all four peptides as off-limits and check with their anti-doping organization.

9. How does the stack relate to GLP-1 therapy?

Recovery peptides are often marketed to people on semaglutide or tirzepatide, with three implied promises. None has human evidence.

• Protecting muscle. Some of the weight lost on GLP-1 drugs is lean mass. No study has shown that BPC-157, TB-500, GHK-Cu or KPV preserves muscle during weight loss. The measures with human evidence, resistance training and adequate protein, are covered in GLP-1 drugs and muscle loss.
• Settling the gut. BPC-157’s and KPV’s gut research is in rodents, plus one small ulcerative colitis enema study for BPC-157 described in FDA’s briefing. None of it tested nausea, constipation or reflux from GLP-1 drugs.
• Healing training injuries. That is the stack’s core claim, and section 3 covers how little human evidence supports it.

There are also no interaction studies between these peptides and GLP-1 drugs. Practical overlaps include more injections (and more injection-site problems), a harder time attributing side effects when several products start at once, and the possibility that a new symptom is blamed on the GLP-1 drug when it came from an untested peptide, or the reverse. Approved GLP-1 drugs went through the manufacturing and safety review the gray-market blends skip; mixing the two in one routine does not lend the second any of the first’s evidence.

10. What would better evidence look like?

For any of these peptides, convincing evidence would be a randomized, placebo-controlled trial in people with the same diagnosed injury, the same rehabilitation in every group, a chemically characterized and sterile product, and outcomes that matter: return to activity, strength, re-injury and imaging, plus systematic safety follow-up. For a blend, the trial would also need arms for each peptide alone, because the claim is that the combination beats its parts. The 2026 rat study is the only experiment so far with that design, and it found no added benefit.

Until such data exist, anyone who used a Wolverine, GLOW or KLOW product can still make their own experience easier to interpret for a clinician: record the exact product and lot, the start and stop dates, every other treatment and training change, and any skin, injection-site or general symptoms, with setbacks as well as good days. A peptide log keeps those details in one place next to any GLP-1 doses.

11. Wolverine Stack FAQ

• What is in the Wolverine stack?

  BPC-157, a synthetic 15-amino-acid peptide, and TB-500, a synthetic 7-amino-acid fragment of the protein thymosin beta-4 (Ac-LKKTETQ). It is marketed for tendon, ligament and muscle recovery. GLOW adds GHK-Cu, a copper peptide studied mainly in skin, and KLOW adds GHK-Cu plus KPV, a 3-amino-acid anti-inflammatory fragment.

• Has the Wolverine stack been tested in humans?

  Not in any controlled trial. The only published human report involving both peptides is a 2021 retrospective chart review in which 4 people received BPC-157 plus thymosin beta-4 knee injections, with no placebo group or imaging. No human study of GLOW or KLOW was found.

• Does combining BPC-157 and TB-500 work better than either alone?

  There is no human evidence that it does. In a 2026 rat study of repaired Achilles tendons, TB-500 alone improved strength and tissue scores most clearly, and the authors reported that the combination did not confer additional benefits over either peptide alone. A rat study cannot settle the question for people.

• Is the Wolverine stack legal to buy or compound in the US?

  None of the peptides is FDA-approved. Since October 30, 2026, an HHS enforcement discretion policy says HHS does not intend to act against 503A pharmacies compounding BPC-157, TB-500, KPV, MOTS-c, semax or epitalon under 10 conditions, one of which is that each product contains only one of those ingredients. So a premixed BPC-157 and TB-500 blend falls outside the policy, and GHK-Cu is not covered. The policy is a draft, nonbinding, and can be withdrawn. 'Research use only' products sold to consumers are a separate, unregulated market.

• What did FDA say about BPC-157 and TB-500 safety?

  FDA's safety summaries flag a risk of immune reactions linked to peptide clumping and impurities, unclear chemical characterization, and little or no human safety data. Its July 2026 staff reviews concluded the evidence weighed against adding BPC-157, TB-500 or KPV to the compounding list. The advisory committee voted 8-6 to recommend them anyway; that vote is not binding.

• Is the Wolverine stack banned in sport?

  Yes. The WADA 2026 Prohibited List names BPC-157 under S0, non-approved substances, and thymosin beta-4 and its derivatives such as TB-500 under S2, growth factors. Both classes are prohibited at all times, in and out of competition. GHK-Cu and KPV are not named, but S0 covers any substance without approval for human therapeutic use.

• Can the Wolverine stack help with GLP-1 side effects or muscle loss?

  No human study has tested it for either. BPC-157's gut research involves rats and a small ulcerative colitis enema study, not GLP-1 nausea, and none of these peptides has been shown to preserve muscle during weight loss. Resistance training and adequate protein are the measures with human evidence.

• What are the risks of gray-market peptide blends?

  Unknown identity and dose, peptide impurities that can trigger immune reactions, and possible bacterial endotoxin or metal contamination. Tests of falsified peptide drugs from illegal online pharmacies found purity between 5% and 75% for some and arsenic above injectable safety limits, and tests of online semaglutide vials found endotoxin in every sample. A blend also makes it impossible to tell which ingredient caused a reaction, as one FDA adverse event report illustrates.

12. Sources